Dr. Angel Yu is a specialty oncology care physician board certified in medical oncology, hematology and internal medicine at Inova Health System. She joined Inova in 2020 and has been in medical practice since 2012. Her area of interest is genitourinary cancers, which include prostate, bladder, kidney, and testicular cancers. She completed her undergraduate education at the University of Pennsylvania with a major in biology, after which she received her doctorate in medicine at the Drexel University College of Medicine. She completed her internal medicine and hematology/oncology training at The George Washington University in Washington, D.C. Prior to joining Inova, Dr. Yu worked as a medical oncologist and hematologist with Novant Health and CaroMont Health, both based in North Carolina. She is excited to return to the D.C. area to focus on providing compassionate, personalized and evidence-based oncology care to patients with genitourinary cancers.

Dr. Yu is highly rated in 18 conditions, according to our data. Her clinical expertise encompasses Renal Cell Carcinoma (RCC), Familial Wilms Tumor 2, Prostate Cancer, and Non-Small Cell Lung Cancer (NSCLC).

She is actively involved in clinical research, co-authoring 12 peer reviewed articles and participating in 11 clinical trials. Dr. Yu is currently accepting new patients.

Specialties

Oncology

Hematology

Licenses

Internal Medicine in VA

Fellowships

George Washington University Medical Center Training Specialty: Hematology and Oncology 7/1/2012 - 6/30/2015

Hospital Affiliations

Inova Alexandria Hospital

Inova Fairfax Hospital

Inova Fair Oaks Hospital

Inova Loudoun Hospital

Inova Alexandria Hospital

Inova Loudoun Hospital

Inova Fair Oaks Hospital

Inova Fairfax Hospital

Languages Spoken

English

Korean

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance

Find your insuranceClose

Accepted insurance plans:

Aetna

Anthem BCBS

Blue Cross Blue Shield

CareFirst

Cigna

Commonwealth Care Alliance

MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
MEDICARE-MEDICAID PLAN

HealthKeepers

Highmark

Humana

HMO
INDEMNITY
POS
PPO

Innovation Health

Johns Hopkins Healthcare

HMO
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE-MEDICAID PLAN

Managed Medicaid

OTHER MANAGED MEDICAID

Medica

Medicaid

OTHER MEDICAID
STATE MEDICAID

Oscar

Piedmont

Sentara Healthcare

INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE ASSISTANCE PROGRAM
MEDICARE MAPD
MEDICARE SNP
OTHER COMMERCIAL
OTHER MEDICARE
OTHER MEDICARE PART D

UnitedHealthcare

Wellcare

EPO
HMO
INSURANCE PLAN
MANAGED MEDICAID PLAN
MEDICARE MAPD
MEDICARE PDP
MEDICARE SNP
MEDICARE-MEDICAID PLAN
OTHER MEDICARE
OTHER MEDICARE PART D

View 14 Less Insurance Carriers -

Locations

Inova Schar Cancer Institute
8081 Innovation Park Dr, Level 5 - Great Falls Clinic, Fairfax, VA 22031

Call: 571-472-1180

Additional Areas of Focus

Dr. Yu has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Prostate Cancer

Bladder Cancer

Testicular Cancer

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)

Enrollment Status: Recruiting

Publish Date: September 08, 2026

Intervention Type: Procedure, Drug, Other, Biological

Study Drugs: Carboplatin, Cisplatin, Gemcitabine Hydrochloride, Paclitaxel, Pembrolizumab, Pemetrexed Disodium

Study Phase: Phase 3

A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial

Enrollment Status: Terminated

Publish Date: September 04, 2026

Intervention Type: Other, Drug

Study Drug: Aspirin

Study Phase: Phase 3

Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer